What Has Been the Progress and Growth of the Drugs for Immunotherapy Market in Recent Years?
The drugs for immunotherapy market has seen considerable growth due to a variety of factors.
• The immunotherapy drugs market has seen a significant expansion in size over the past few years. The market, which is set to balloon from $255.14 billion in 2024 to $281.43 billion in 2025, is expected to see a compound annual growth rate (CAGR) of 10.3%.
Factors such as an increased prevalence of cancer, uncatered medical requirements, heightened awareness about cancer immunotherapy, attractive adoption rates of immunotherapy techniques, and increased investments from major pharmaceutical entities have contributed to the surge in the growth rate registered in the past years.
What Can Be Expected from the Drugs for Immunotherapy Market Size?
The drugs for immunotherapy market is expected to maintain its strong growth trajectory in upcoming years.
• The immunotherapy drugs market is projected to witness swift expansion in the ensuing years, escalating to a remarkable $445.12 billion by 2029, with a 12.1% Compound Annual Growth Rate (CAGR). This growth within the forecasted period could be credited to factors such as the proliferation of combination treatments, customization in medicine, worldwide expansion, biomarker-guided therapies, and a rise in clinical trials. The major impending trends include advancements in the realm of immunology, car-t cell therapies, targeted immunotherapies, combinations of immunotherapy, and the development of neoantigen vaccines.
What Are the Critical Driver Fuelling The Drugs for Immunotherapy Market's Growth?
The market for immunotherapy drugs is propelled by an increasing number of cancer cases worldwide. A few of the most common cancer origins are obesity, smoking, alcohol consumption, and unhealthy eating. For example, Macmillan Cancer Support, the UK's top health charity, estimates that by 2025 there will be 3.5 million cancer sufferers, 4 million by 2030, and 5.3 million by 2040. The most common types of cancers are those of the breast, lung, colon, rectum, and prostate. About one third of cancer deaths can be attributed to the use of tobacco, high body mass index, alcohol consumption, a diet low in fruits and vegetables, and a lack of exercise. It's predicted that as cancer cases continue to rise, so will the demand for immunotherapy drugs, subsequently giving a boost to the growth of the immunotherapy drugs market.
How Is The Drugs for Immunotherapy Market segmented?
The drugs for immunotherapy market covered in this report is segmented –
1) By Type: Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types
2) By Therapy Area: Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas
3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Interferons: Interferon Alfa, Interferon Beta, Interferon Gamma
3) By Interleukins: Interleukin-2 (IL-2), Interleukin-6 (IL-6), Interleukin-12 (IL-12)
4) By Vaccines: Preventive Vaccines, Therapeutic Vaccines
5) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
6) By Other Types: Cancer Cell Therapies, Cytokine Therapy, T-Cell Receptor Therapy
Pre-Book The Drugs for Immunotherapy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Drugs for Immunotherapy Market?
Major corporations in the immunotherapy drugs market are concentrating their efforts on developing new products like Keytruda (pembrolizumab) to better serve their clients. Keytruda (pembrolizumab) is a unique form of immunotherapy that uses an immune checkpoint inhibitor medication designed for adult patients. For example, Merck & Co., Inc., a pharmaceutical company based in the US, introduced Keytruda (pembrolizumab) in January 2023. This product, which was sanctioned by the US-based federal agency, the Food and Drug Administration, is used in the treatment of various cancers by collaborating with the immune system to battle cancer cells. As an adjuvant therapy for non-small cell lung cancer (NSCLC), KEYTRUDA (pembrolizumab) has been approved. This advancement in cancer care is significant and is predicted to positively influence the healthcare industry.
Who Are the Key Players In The Drugs for Immunotherapy Market?
Major companies operating in the drugs for immunotherapy market include:
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Amgen Inc.
• AbbVie Inc.
• Merck & Co. Inc.
• GlaxoSmithKline plc
• Eli Lilly and Company
• Bristol-Myers Squibb
• AstraZeneca plc
• Johnson & Johnson
• UbiVac
• Pfizer Inc.
• Sanofi SA
• Bayer AG
• Celgene Corporation
• Incyte Corporation
• Juno Therapeutics Inc.
• Bluebird bio
• Celldex Therapeutics
• BeiGene
• BioNTech AG
• CytomX Therapeutics
• Eisai Co. Ltd.
• Flexus Biosciences Inc.
• Genscript Biotech Corporation
• Gilead Sciences Inc.
• Harpoon Therapeutics Inc.
• Heptares Therapeutics Ltd.
• Ignyta Inc.
• Immatics Biotechnologies
• Jounce Therapeutics Inc.
What Is The Most Dominant Region In The Drugs for Immunotherapy Market?
North America was the largest region in the immunotherapy market in 2024. Middle East is expected to be the fastest growing region in the drug for immunotherapy market report during the forecast period. The regions covered in the drugs for immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
